FOBs: Industry Begins To Plot Course Along Pathway As It Awaits FDA Policy

Everyone in the drug industry is eagerly waiting for any sign from FDA as to how it will handle biosimilar applications. So a recent meeting with a session devoted to FDA's current position on follow-on biologics was particularly tantalizing